Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1993 Oct;48(10):985–989. doi: 10.1136/thx.48.10.985

Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment.

K J Holroyd 1, R Buhl 1, Z Borok 1, J H Roum 1, A D Bokser 1, G J Grimes 1, D Czerski 1, A M Cantin 1, R G Crystal 1
PMCID: PMC464806  PMID: 8256245

Abstract

BACKGROUND--Concentrations of glutathione, a ubiquitous tripeptide with immune enhancing and antioxidant properties, are decreased in the blood and lung epithelial lining fluid of human immunodeficiency virus (HIV) seropositive individuals. Since the lung is the most common site of infection in those who progress to AIDS it is rational to consider whether it is possible to safely augment glutathione levels in the epithelial lining fluid of HIV seropositive individuals, thus potentially improving local host defence. METHODS--Purified reduced glutathione was delivered by aerosol to HIV seropositive individuals (n = 14) and the glutathione levels in lung epithelial lining fluid were compared before and at one, two, and three hours after aerosol administration. RESULTS--Before treatment total glutathione concentrations in the epithelial lining fluid were approximately 60% of controls. After three days of twice daily doses each of 600 mg reduced glutathione, total glutathione levels in the epithelial lining fluid increased and remained in the normal range for at least three hours after treatment. Strikingly, even though > 95% of the glutathione in the aerosol was in its reduced form, the percentage of oxidised glutathione in epithelial lining fluid increased from 5% before treatment to about 40% three hours after treatment, probably reflecting the use of glutathione as an antioxidant in vivo. No adverse effects were observed. CONCLUSIONS--It is feasible and safe to use aerosolised reduced glutathione to augment the deficient glutathione levels of the lower respiratory tract of HIV seropositive individuals. It is rational to evaluate further the efficacy of this tripeptide in improving host defence in HIV seropositive individuals.

Full text

PDF
989

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bannai S., Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol. 1986;89(1):1–8. doi: 10.1007/BF01870891. [DOI] [PubMed] [Google Scholar]
  2. Bradburne R. M., Ettensohn D. B., Opal S. M., McCool F. D. Relapse of Pneumocystis carinii pneumonia in the upper lobes during aerosol pentamidine prophylaxis. Thorax. 1989 Jul;44(7):591–593. doi: 10.1136/thx.44.7.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Buhl R., Jaffe H. A., Holroyd K. J., Wells F. B., Mastrangeli A., Saltini C., Cantin A. M., Crystal R. G. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 1989 Dec 2;2(8675):1294–1298. doi: 10.1016/s0140-6736(89)91909-0. [DOI] [PubMed] [Google Scholar]
  4. Buhl R., Vogelmeier C., Critenden M., Hubbard R. C., Hoyt R. F., Jr, Wilson E. M., Cantin A. M., Crystal R. G. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4063–4067. doi: 10.1073/pnas.87.11.4063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cantin A. M., North S. L., Hubbard R. C., Crystal R. G. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985) 1987 Jul;63(1):152–157. doi: 10.1152/jappl.1987.63.1.152. [DOI] [PubMed] [Google Scholar]
  6. Carson D. A., Seto S., Wasson D. B. Lymphocyte dysfunction after DNA damage by toxic oxygen species. A model of immunodeficiency. J Exp Med. 1986 Mar 1;163(3):746–751. doi: 10.1084/jem.163.3.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chandra A., Demirhan I., Arya S. K., Chandra P. D-penicillamine inhibits transactivation of human immunodeficiency virus type-1 (HIV-1) LTR by transactivator protein. FEBS Lett. 1988 Aug 29;236(2):282–286. doi: 10.1016/0014-5793(88)80038-3. [DOI] [PubMed] [Google Scholar]
  8. Edelman A. S., Zolla-Pazner S. AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. FASEB J. 1989 Jan;3(1):22–30. doi: 10.1096/fasebj.3.1.2562947. [DOI] [PubMed] [Google Scholar]
  9. Folks T. M., Clouse K. A., Justement J., Rabson A., Duh E., Kehrl J. H., Fauci A. S. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2365–2368. doi: 10.1073/pnas.86.7.2365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Halliwell B., Cross C. E. Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Sense or speculation? Arch Intern Med. 1991 Jan;151(1):29–31. [PubMed] [Google Scholar]
  11. Heffner J. E., Repine J. E. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis. 1989 Aug;140(2):531–554. doi: 10.1164/ajrccm/140.2.531. [DOI] [PubMed] [Google Scholar]
  12. Hoffeld J. T., Oppenheim J. J. Enhancement of the primary antibody response by 2-mercaptoethanol is mediated by its action on glutathione in the serum. Eur J Immunol. 1980 May;10(5):391–395. doi: 10.1002/eji.1830100514. [DOI] [PubMed] [Google Scholar]
  13. Kubota S., el-Farrash M. A., Maki M., Harada S., Hatanaka M. 2,3 Dimercapto-1-propanol inhibits HIV-1 tat activity, viral production, and infectivity in vitro. AIDS Res Hum Retroviruses. 1990 Jul;6(7):919–927. doi: 10.1089/aid.1990.6.919. [DOI] [PubMed] [Google Scholar]
  14. Levy J. A. Mysteries of HIV: challenges for therapy and prevention. Nature. 1988 Jun 9;333(6173):519–522. doi: 10.1038/333519a0. [DOI] [PubMed] [Google Scholar]
  15. Liang C. M., Lee N., Cattell D., Liang S. M. Glutathione regulates interleukin-2 activity on cytotoxic T-cells. J Biol Chem. 1989 Aug 15;264(23):13519–13523. [PubMed] [Google Scholar]
  16. Meister A., Anderson M. E. Glutathione. Annu Rev Biochem. 1983;52:711–760. doi: 10.1146/annurev.bi.52.070183.003431. [DOI] [PubMed] [Google Scholar]
  17. Meister A. Glutathione metabolism and its selective modification. J Biol Chem. 1988 Nov 25;263(33):17205–17208. [PubMed] [Google Scholar]
  18. Messina J. P., Lawrence D. A. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol. 1989 Sep 15;143(6):1974–1981. [PubMed] [Google Scholar]
  19. Murray J. F., Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1356–1372. doi: 10.1164/ajrccm/141.5_Pt_1.1356. [DOI] [PubMed] [Google Scholar]
  20. Paller M. S. Hypothyroidism protects against free radical damage in ischemic acute renal failure. Kidney Int. 1986 Jun;29(6):1162–1166. doi: 10.1038/ki.1986.122. [DOI] [PubMed] [Google Scholar]
  21. Rennard S. I., Basset G., Lecossier D., O'Donnell K. M., Pinkston P., Martin P. G., Crystal R. G. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) 1986 Feb;60(2):532–538. doi: 10.1152/jappl.1986.60.2.532. [DOI] [PubMed] [Google Scholar]
  22. Roederer M., Ela S. W., Staal F. J., Herzenberg L. A., Herzenberg L. A. N-acetylcysteine: a new approach to anti-HIV therapy. AIDS Res Hum Retroviruses. 1992 Feb;8(2):209–217. doi: 10.1089/aid.1992.8.209. [DOI] [PubMed] [Google Scholar]
  23. Roederer M., Staal F. J., Raju P. A., Ela S. W., Herzenberg L. A., Herzenberg L. A. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4884–4888. doi: 10.1073/pnas.87.12.4884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenberg Z. F., Fauci A. S. Immunopathogenesis of HIV infection. FASEB J. 1991 Jul;5(10):2382–2390. doi: 10.1096/fasebj.5.10.1676689. [DOI] [PubMed] [Google Scholar]
  25. Saltini C., Hance A. J., Ferrans V. J., Basset F., Bitterman P. B., Crystal R. G. Accurate quantification of cells recovered by bronchoalveolar lavage. Am Rev Respir Dis. 1984 Oct;130(4):650–658. doi: 10.1164/arrd.1984.130.4.650. [DOI] [PubMed] [Google Scholar]
  26. Staal F. J., Ela S. W., Roederer M., Anderson M. T., Herzenberg L. A., Herzenberg L. A. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 1992 Apr 11;339(8798):909–912. doi: 10.1016/0140-6736(92)90939-z. [DOI] [PubMed] [Google Scholar]
  27. Stacey N. H., Craig G. K. Role of thiols in human peripheral blood natural killer and killer lymphocyte activities. Experientia. 1989 Feb 15;45(2):180–181. doi: 10.1007/BF01954868. [DOI] [PubMed] [Google Scholar]
  28. Stagnaro R., Pierri I., Piovano P., Baracco F., De Palma M., Indiveri F. Thiol containing antioxidant drugs and the human immune system. Bull Eur Physiopathol Respir. 1987 Jul-Aug;23(4):303–307. [PubMed] [Google Scholar]
  29. Suthanthiran M., Anderson M. E., Sharma V. K., Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc Natl Acad Sci U S A. 1990 May;87(9):3343–3347. doi: 10.1073/pnas.87.9.3343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sönnerborg A., Carlin G., Akerlund B., Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scand J Infect Dis. 1988;20(3):287–290. doi: 10.3109/00365548809032453. [DOI] [PubMed] [Google Scholar]
  31. Sönnerborg A., Jarstrand C. Nitroblue tetrazolium (NBT) reduction by neutrophilic granulocytes in patients with HTLV-III infection. Scand J Infect Dis. 1986;18(2):101–103. doi: 10.3109/00365548609032314. [DOI] [PubMed] [Google Scholar]
  32. Wendel A., Cikryt P. The level and half-life of glutathione in human plasma. FEBS Lett. 1980 Nov 3;120(2):209–211. doi: 10.1016/0014-5793(80)80299-7. [DOI] [PubMed] [Google Scholar]
  33. Yoda Y., Nakazawa M., Abe T., Kawakami Z. Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. Cancer Res. 1986 May;46(5):2551–2556. [PubMed] [Google Scholar]
  34. el-Hag A., Lipsky P. E., Bennett M., Clark R. A. Immunomodulation by neutrophil myeloperoxidase and hydrogen peroxide: differential susceptibility of human lymphocyte functions. J Immunol. 1986 May 1;136(9):3420–3426. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES